NextCell Pharma AB (NXTCL.ST)
SEK 1.14
(7.17%)
SEK 1.14
(7.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 81.28 Million SEK | -8.49% |
| 2023 | 88.82 Million SEK | -28.74% |
| 2022 | 124.65 Million SEK | -19.9% |
| 2021 | 155.62 Million SEK | 422.69% |
| 2020 | 29.77 Million SEK | 11.44% |
| 2019 | 26.71 Million SEK | 213.95% |
| 2018 | 8.51 Million SEK | -60.65% |
| 2017 | 21.62 Million SEK | 128.47% |
| 2016 | 9.46 Million SEK | -23.41% |
| 2015 | 12.35 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 81.28 Million SEK | 32.99% |
| 2024 Q3 | 61.12 Million SEK | -13.35% |
| 2024 Q2 | 70.54 Million SEK | -13.14% |
| 2024 Q1 | 81.21 Million SEK | -8.57% |
| 2023 Q3 | 95.63 Million SEK | -10.29% |
| 2023 Q2 | 106.59 Million SEK | -8.05% |
| 2023 FY | 88.82 Million SEK | -28.74% |
| 2023 Q4 | 88.82 Million SEK | -7.12% |
| 2023 Q1 | 115.93 Million SEK | -6.99% |
| 2022 Q1 | 152.55 Million SEK | -1.97% |
| 2022 Q2 | 141.42 Million SEK | -7.3% |
| 2022 Q3 | 132.71 Million SEK | -6.16% |
| 2022 Q4 | 124.65 Million SEK | -6.07% |
| 2022 FY | 124.65 Million SEK | -19.9% |
| 2021 Q1 | 24.43 Million SEK | -17.94% |
| 2021 FY | 155.62 Million SEK | 422.69% |
| 2021 Q4 | 155.62 Million SEK | -2.86% |
| 2021 Q3 | 160.2 Million SEK | 2.1% |
| 2021 Q2 | 156.91 Million SEK | 542.18% |
| 2020 Q1 | 22.7 Million SEK | -15.02% |
| 2020 FY | 29.77 Million SEK | 11.44% |
| 2020 Q4 | 29.77 Million SEK | 126.5% |
| 2020 Q3 | 13.14 Million SEK | -29.68% |
| 2020 Q2 | 18.69 Million SEK | -17.67% |
| 2019 Q2 | 12.46 Million SEK | -23.07% |
| 2019 FY | 26.71 Million SEK | 213.95% |
| 2019 Q4 | 26.71 Million SEK | 189.74% |
| 2019 Q3 | 9.22 Million SEK | -26.04% |
| 2019 Q1 | 16.2 Million SEK | 90.45% |
| 2018 Q4 | 8.51 Million SEK | -15.71% |
| 2018 FY | 8.51 Million SEK | -60.65% |
| 2018 Q1 | 18.3 Million SEK | -15.37% |
| 2018 Q3 | 10.09 Million SEK | -28.68% |
| 2018 Q2 | 14.15 Million SEK | -22.66% |
| 2017 Q2 | 7.78 Million SEK | 0.0% |
| 2017 FY | 21.62 Million SEK | 128.47% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q3 | 10.42 Million SEK | 33.92% |
| 2017 Q4 | 21.62 Million SEK | 107.54% |
| 2016 FY | 9.46 Million SEK | -23.41% |
| 2016 Q4 | 9.46 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | 12.35 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Active Biotech AB (publ) | 44 Million SEK | -84.745% |
| Biovica International AB (publ) | 131.4 Million SEK | 38.141% |
| Cantargia AB (publ) | 223.71 Million SEK | 63.664% |
| CombiGene AB (publ) | 120.61 Million SEK | 32.604% |
| Cyxone AB (publ) | 43.65 Million SEK | -86.206% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -185.141% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -169.406% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -3.299% |
| Fluicell AB (publ) | 9.34 Million SEK | -770.321% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 76.863% |
| Mendus AB (publ) | 755.95 Million SEK | 89.247% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 42.184% |
| I-Tech AB | 152.44 Million SEK | 46.676% |
| Intervacc AB (publ) | 259.61 Million SEK | 68.689% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -141.914% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 70.838% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -305.609% |
| OncoZenge AB (publ) | 20.34 Million SEK | -299.646% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -30.317% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 87.561% |
| Lipum AB (publ) | 12.11 Million SEK | -571.247% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 31.374% |
| Ziccum AB (publ) | 14.97 Million SEK | -442.934% |
| BioArctic AB (publ) | 1.18 Billion SEK | 93.146% |
| Genovis AB (publ.) | 288.85 Million SEK | 71.859% |
| Camurus AB (publ) | 1.9 Billion SEK | 95.739% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 54.106% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -30.789% |
| Aptahem AB (publ) | 63.02 Million SEK | -28.978% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 83.619% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 89.378% |
| Kancera AB (publ) | 65.64 Million SEK | -23.833% |
| Saniona AB (publ) | 64.14 Million SEK | -26.729% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -53.417% |
| AcouSort AB (publ) | 34.51 Million SEK | -135.529% |
| Xintela AB (publ) | 18.39 Million SEK | -341.903% |
| Abliva AB (publ) | 87.49 Million SEK | 7.098% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 93.54% |
| Amniotics AB (publ) | 26.08 Million SEK | -211.615% |
| 2cureX AB (publ) | 16.62 Million SEK | -388.95% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1237.634% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 95.723% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 92.015% |
| Biosergen AB | 7.2 Million SEK | -1028.843% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -93.732% |
| Corline Biomedical AB | 100.1 Million SEK | 18.797% |
| Nanologica AB (publ) | 77.42 Million SEK | -4.984% |
| LIDDS AB (publ) | 17.65 Million SEK | -360.425% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 89.307% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 94.194% |
| SynAct Pharma AB | 228.01 Million SEK | 64.35% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -203.733% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -274.55% |
| Alzinova AB (publ) | 123.18 Million SEK | 34.014% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 6.643% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 65.9% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -861.419% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 4.622% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -446.695% |
| Simris Alg AB (publ) | 174.55 Million SEK | 53.43% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 62.547% |